Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tacrolimus with daclizumab versus steroids in HCV-positive liver transplant recipients
2004-004561-14Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tacrolimus, daclizumab, methylprednisolone and prednisone in hepatitis C virus infection and Cirrhosis (2 arms), sponsored by Astellas Pharma. Primary endpoint: Hepatitis C viral load at 12 months post transplantation. Started Mar 2005; status: completed.
02
Drugs
tacrolimusdaclizumabmethylprednisoloneprednisone
03
Conditions
hepatitis C virus infectionCirrhosis
Beyond the preview
Go deeper on 2004-004561-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004561-14.